Methods for Modulating the Efficacy of Nucleic Acid Based Therapies
AssigneesEleos, Inc., Smith Holdings, LLC
InventorsDayton T. Reardan, Larry J. Smith, Robert E. Klem
Life of this patent
Estimating the term…
Abstract
Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens associated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders. Also provided are methods for modulating the efficacy of nucleic acid based therapeutics.
Claims32
1-51. (canceled)
A method for modulating the efficacy of a nucleic acid based therapeutic which inhibits expression of a target nucleic acid, comprising
- a) exposing said therapeutic to an agent under conditions suitable for a chemical reaction with said therapeutic, if any is present;
- b) assessing whether said agent alters the molecular configuration of the nucleic acid based therapeutic or alters the attractive interaction between the therapeutic and the nucleic acid target;
- said method further comprising providing a packaged pharmaceutical preparation of the nucleic acid based therapeutic to be administered wherein the instructions additionally include contraindication and adverse reaction information pertaining to agent(s) identified in step b) in the packaged pharmaceutical composition.
A method for modulating the efficacy of a nucleic acid based therapeutic composition which inhibits expression of a target nucleic acid, comprising eliminating exposure to acetaminophen in a patient being treated with said therapeutic, said acetaminophen alkylating one or more of bases of said therapeutic, said method comprising providing a packaged pharmaceutical preparation of the composition to be administered wherein the instructions additionally include contraindication and adverse reaction information pertaining to the packaged pharmaceutical composition.
A method for modulating the efficacy of a nucleic acid based therapeutic which inhibits expression of a target nucleic acid by controlling for exposure to acetaminophen in a patient in need thereof, said method comprising providing a packaged pharmaceutical preparation of the composition to be administered wherein the instructions additionally include contraindication and adverse reaction information pertaining to the packaged Pharmaceutical Composition.
A method for increasing the efficacy of nucleic acid-based therapy which is effective to down modulate expression of a target gene comprising administering a composition comprising a therapeutic amount of a nucleic acid based therapeutic to a human in need thereof, and instructing said human to avoid administration of acetaminophen so that the composition and acetaminophen are not present in the human in vivo at the time the composition is producing its therapeutic effect.
Dependencies are inferred from the claim text.